Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab von Lin, Simeng, Kennedy, Nicholas A., Saifuddin, Aamir, Sandoval, Diana Muñoz, Reynolds, Catherine J., Seoane, Rocio Castro, Kottoor, Sherine H., Pieper, Franziska P., Lin, Kai-Min, Butler, David K., Chanchlani, Neil, Nice, Rachel, Chee, Desmond, Bewshea, Claire, Janjua, Malik, McDonald, Timothy J., Sebastian, Shaji, Alexander, James L., Constable, Laura, Lee, James C., Murray, Charles D., Hart, Ailsa L., Irving, Peter M., Jones, Gareth-Rhys, Kok, Klaartje B., Lamb, Christopher A., Lees, Charlie W., Altmann, Daniel M., Boyton, Rosemary J., Goodhand, James R., Powell, Nick, Ahmad, Tariq

Volltext